Abingworth’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Abingworth’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-925,000	Closed	-$3.42M	–	17
2017 Q4	$3.42M	Hold	925,000	–	–	2.48%	9
2017 Q3	$3.78M	Hold	925,000	–	–	2.62%	7
2017 Q2	$3.43M	Hold	925,000	–	–	2.73%	5
2017 Q1	$3.83M	Buy	+925,000	New	+$3.89M	2.85%	5

Abingworth's CASC Position: Q1 2018 in Review

Abingworth sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 925,000 shares — an estimated $3.42M sold.

Abingworth first reported a position in CASC in Q1 2017 and held it in 4 quarters. The position peaked at $3.83M in Q1 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

Abingworth reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Abingworth sold 925,000 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $3.42M.
Abingworth first reported a position in Cascadian Therapeutics, Inc. in Q1 2017 and held it in 4 quarters.
Abingworth's Cascadian Therapeutics, Inc. position peaked at $3.83M in Q1 2017.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Abingworth's 13F filing for Q1 2018, filed 15 May 2018.